The PARCC (Paris Cardiovascular Research Center, Inserm U970) succeeded in bringing together an important critical mass of basic and clinician scientists, who share a vision and common objectives in the field of cardiovascular diseases. PARCC teams are conducting projects, spanning basic molecular and cellular biology to integrated physiology and pathophysiology, biomarkers, genetics and epidemiology, with the goal of understanding, at a more refined and mechanistic level, disease processes in atherosclerosis, angiogenesis, hypertension, heart failure and sudden cardiac death, and also at the interface between cardiology and oncology. They are developing novel diagnostic and therapeutic strategies. Translational research is an integral part of the mission of the PARCC, in close connection with clinical laboratories and departments of the HEGP hospital.
The PARCC is part of the Université de Paris.More
International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nat Rev Endocrinol, July 2021
Endothelial Cell Indoleamine 2, 3-Dioxygenase 1 Alters Cardiac Function After Myocardial Infarction Through Kynurenine. Circulation 2021 Feb 9;143(6):566-580.
Team 08 is recruiting a post-doctoral fellow to work on cell metabolism in kidney inflammation. Post-doc in team 8.
Team 04 is recruiting a statistician to work on cardiovascular epidemiology. Job offer Team 04
Team 13 is recruiting a post-doctoral fellow to work on microRNAs, oncometabolites and tumor microenvironment : post-doc in Favier Lab 2020
Team 01 is recruiting a post-doctoral fellow to work on on mechanisms of extracellular vesicle release and biodistribution in the context of cardiovascular diseasedevelopment : postdoc PARCC